CCA
SWTX

Catalyst Capital Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Catalyst Capital Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-260
Closed -$6K – 407
2019
Q3 		$6K Buy
+260
New +$6.15K ﹤0.01% 389

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's SWTX Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2019, closing a stake of 260 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in SWTX in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 57 funds tracked by Wall St. Rank hold SWTX as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 260 SpringWorks Therapeutics shares in Q4 2019, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's SpringWorks Therapeutics position peaked at $6K in Q3 2019.
  • 57 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.